SutroVax announces Scientific Advisory Board addition
Forrest, who was a vice president at Wyeth Pharmaceuticals, brings significant expertise in vaccine development to SutroVax.
"Dr. Forrest is renowned for his prominent role in bringing a number of critically important conjugate vaccines to the market including Prevnar, the most commercially successful vaccine of all time," Grant Pickering, CEO of SutroVax, said. "His development expertise will be invaluable as we work to harness the Xpress CF platform to deliver the next generation of vaccines to address major and persistent infectious diseases."
Forrest previously oversaw post-discovery development activities in Wyeth Vaccines Research including Prevnar 13, a 9-valent pneumococcal conjugate vaccine and combinations, FluMist, and RotaShield.
He also worked at Chiron Corporation where he was the global clinical team leader for Menjugate, as well as the adult and adolescent acellular pertussis vaccine program.
"The SutroVax technology is uniquely enabling," Forrest said. "The ability to conjugate site-specifically may well allow the development of broader spectrum vaccines than available today and more potent conjugates to create novel vaccines beyond the reach of other technologies. I look forward to working with the SutroVax team to realize the full potential of this platform."